Back to Search Results

A multicenter randomized controlled trial of intravenous magnesium for sickle cell pain crisis in children.

Pediatric Emergency Medicine, Medical College of Wisconsin, and the Children's Research Institute, Milwaukee, WI; Pediatric Hematology and Oncology/Blood Research Institute, Medical College of Wisconsin, and the Children's Research Institute, Milwaukee, WI; Pediatric Emergency Medicine, Johns Hopkins University, Baltimore, MD; Pediatric Hematology and Oncology, Children's National Medical Center, Washington, DC; Pediatric Emergency Medicine and. Pediatric Hematology and Oncology, Baylor College of Medicine/Texas Children's Hospital, Houston, TX; Pediatric Emergency Medicine, Children's Hospital of Philadelphia, Philadelphia, PA; Pediatric Hematology and Oncology, Children's Hospital of Philadelphia, Philadelphia, PA; Pediatric Emergency Medicine, Wayne State University/Children's Hospital of Michigan, Detroit, MI; Pediatric Hematology and Oncology, Wayne State University/Children's Hospital of Michigan, Detroit, MI; University of Utah/Pediatric Emergency Care Applied Research Network Data Coordinating Center, Salt Lake City, UT; Pediatric Emergency Medicine, Nationwide Children's Hospital, Columbus, OH; Division of Pediatric Hematology and Oncology, Washington University School of Medicine, St. Louis, MO; Division of Emergency Medicine and. Hematology, Oncology & Stem Cell Transplant, Ann & Robert H. Lurie Children's Hospital of Chicago, Northwestern University Feinberg School of Medicine, Chicago, IL; Pediatric Emergency Medicine, Children's Hospital of Pittsburgh of University of Pittsburgh Medical Center, Pittsburgh, PA; and. Department of Pediatrics, Aflac Cancer and Blood Disorders Center, Emory University School of Medicine, Atlanta, GA; Pediatric Hematology and Oncology, Children's Hospital of Pittsburgh of University of Pittsburgh Medical Center, Pittsburgh, PA; Pediatric Hematology and Oncology, Medical College of Wisconsin, and the Children's Research Institute, Milwaukee, WI.

Blood. 2015;(14):1651-7
Full text from:

Other resources

Abstract

Magnesium, a vasodilator, anti-inflammatory, and pain reliever, could alter the pathophysiology of sickle cell pain crises. We hypothesized that intravenous magnesium would shorten length of stay, decrease opioid use, and improve health-related quality of life (HRQL) for pediatric patients hospitalized with sickle cell pain crises. The Magnesium for Children in Crisis (MAGiC) study was a randomized, double-blind, placebo-controlled trial of intravenous magnesium vs normal saline placebo conducted at 8 sites within the Pediatric Emergency Care Applied Research Network (PECARN). Children 4 to 21 years old with hemoglobin SS or Sβ(0) thalassemia requiring hospitalization for pain were eligible. Children received 40 mg/kg of magnesium or placebo every 8 hours for up to 6 doses plus standard therapy. The primary outcome was length of stay in hours from the time of first study drug infusion, compared using a Van Elteren test. Secondary outcomes included opioid use and HRQL. Of 208 children enrolled, 204 received the study drug (101 magnesium, 103 placebo). Between-group demographics and prerandomization treatment were similar. The median interquartile range (IQR) length of stay was 56.0 (27.0-109.0) hours for magnesium vs 47.0 (24.0-99.0) hours for placebo (P = .24). Magnesium patients received 1.46 mg/kg morphine equivalents vs 1.28 mg/kg for placebo (P = .12). Changes in HRQL before discharge and 1 week after discharge were similar (P > .05 for all comparisons). The addition of intravenous magnesium did not shorten length of stay, reduce opioid use, or improve quality of life in children hospitalized for sickle cell pain crisis. This trial was registered at www.clinicaltrials.gov as #NCT01197417.

Methodological quality

Metadata

MeSH terms : Magnesium ; Vasodilator Agents